

REMARKS

Applicants amended the title of the invention to remove the French word “et” and replace that word with “and,” the English translation of “et.” No new matter is added by this amendment.

The Examiner required restriction under 35 U.S.C. § 121 between the following groups of claims:

Group 1: Claims 1-16, drawn to an assay, biochip, device and a kit for analyzing target nucleic acids;

Group 2: Claims 17-23, drawn to a method for detecting target nucleic acids in a sample;

Group 3: Claim 24, drawn to a method of using a biochip for determining the editing rate of an mRNA encoding a membrane receptor from a mammalian cell;

Group 4: Claims 25-27, 34, 38, and 39, drawn to a method for selecting a compound capable of modulating the editing of an mRNA;

Group 5: Claims 28-33, drawn to an SSCP method for obtaining an editing profile of an mRNA;

Group 6: Claims 35 and 36, drawn to a method for selecting a compound capable of preventing and treating in a patient; and

Group 7: Claim 37, drawn to a method of diagnosing a disease associated with mRNA editing.


Solely to facilitate prosecution and without prejudice or disclaimer, Applicants provisionally elect to prosecute Group 5, claims 28-33.

Please grant any extensions of time required to enter this paper and charge necessary fees for such an extension to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 11, 2008

By: 
Maryann T. Puglielli
Reg. No. 52,138